Moberg Pharma Secures U.S. Patent for MOB-015 Dosing

STOCKHOLM, Nov. 3, 2026 – Moberg Pharma AB (OMX: MOB) announced that the United States Patent and Trademark Office has granted a patent covering an improved dosing regimen for its topical onychomycosis candidate, MOB-015. The approval adds a layer of legal protection for the product in the United States, the largest market for dermatology drugs.

U.S. Patent Protects New Dosing Regimen for MOB-015

The USPTO patent specifically covers the revised dosing schedule that Moberg Pharma believes will improve patient adherence. This is the first major market to issue a dosing-related patent for the asset. The company already holds patents for MOB-015 in the European Union, Canada, Japan and China, covering new topical allylamine formulations. The U.S. grant strengthens the overall IP portfolio and gives the company a firmer footing for licensing talks with larger partners.

Global Patent Portfolio Expands Across Key Regions

Moberg Pharma has a track record of securing protection in major jurisdictions. Recent filings confirm patents in Japan and China, adding to earlier grants in the EU, U.S. and Canada. Coverage in China is especially important because the Asian market accounts for a large share of global dermatology demand. With patents in place, the company can limit generic competition during the launch window and negotiate from a position of strength.

Topical Antifungal Market Shows Steady Growth

According to TrendX Insights’ Topical Drug Market, the global market for topical therapies is expected to reach $16.71 billion by 2034, growing at a 7.8% compound annual rate from a 2025 base of $8.50 billion. Onychomycosis remains common, and patients often prefer topical options because they avoid the side effects of oral drugs. The improved dosing schedule of MOB-015 could boost compliance and outcomes, giving Moberg Pharma a competitive edge as the market expands.

Implications for Moberg Pharma’s Development Path

The U.S. patent provides the legal foundation needed for upcoming regulatory submissions and commercial plans. With IP secured, the company can pursue partnerships to fund late-stage development and launch activities. Future filings are expected in additional regions to create a truly global protection net.

The milestone underscores Moberg Pharma’s commitment to delivering a viable onychomycosis treatment and supports long-term value creation for shareholders. For more updates, visit the Press Release Archives.